SCHEMBL27552160

SCHEMBL27552160

CCC(Cl)CCCNc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
MAPT P10636 3/20 0.55
L3MBTL1 Q9Y468 2/20 0.40
KCNH3 Q9ULD8 1/20 0.38
HTR2A P28223 1/20 0.38
HRH1 P35367 1/20 0.38
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
KDM4E B2RXH2 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16234268 0.81 ALDH1A1 (0.59) ALDH1A1MAPTL3MBTL1KCNH3HTR2A
SCHEMBL10606669 0.80 ALDH1A1 (0.57) ALDH1A1MAPTL3MBTL1KCNH3HTR2A
SCHEMBL2255790 0.77 ALDH1A1 (0.64) ALDH1A1MAPTL3MBTL1KCNH3HTR2A
SCHEMBL28681649 0.76 ALDH1A1 (0.57) ALDH1A1MAPTL3MBTL1KCNH3HTR2A
SCHEMBL11046087 0.75 ALDH1A1 (0.55) ALDH1A1MAPTL3MBTL1KCNH3HTR2A
SCHEMBL11040887 0.75 ALDH1A1 (0.55) ALDH1A1MAPTL3MBTL1KCNH3SMN1; SMN2
SCHEMBL11350829 0.75 ALDH1A1 (0.50) ALDH1A1MAPTKCNH3KDM4ENPSR1
SCHEMBL20318842 0.75 ALDH1A1 (0.50) ALDH1A1MAPTL3MBTL1KCNH3CYP1A2
SCHEMBL49577 0.74 ALDH1A1 (0.73) ALDH1A1MAPTL3MBTL1KCNH3KDM4E
SCHEMBL9572773 0.74 MAPT (0.59) ALDH1A1MAPTL3MBTL1KCNH3HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1175246-A Substituted azetidin-2-ones for treatment of atherosclerosis SMITHKLINE BEECHAM PLC (GB) 1998-03-04 CN disclosed